Madrigal Pharmaceuticals Inc

NASDAQ:MDGL   3:59:54 PM EDT
55.89
-5.71 (-9.27%)
Products, Regulatory

Madrigal Provides Update On Timeline For Results From Phase 3 Trial Of Resmetirom

Published: 12/30/2021 14:25 GMT
Madrigal Pharmaceuticals Inc (MDGL) - Madrigal Provides Update on Timeline for Topline Results From the Phase 3 Maestro-nafld-1 Clinical Trial of Resmetirom.
Madrigal Provides Update on Timeline for Topline Results From Phase 3 Maestro-nafld-1 Clinical Trial of Resmetirom.
Madrigal Pharmaceuticals Inc - Expect to Announce Topline 52-week Results From Study in January 2022.